title: Primary radiation therapy in patients with localized orbital marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue (MALT Lymphoma).
abstract: OBJECTIVE
  To evaluate the outcomes of patients with localized orbital marginal zone B-cell lymphoma of the mucosa-associated lymphoid tissue (MALT lymphoma) who were treated with radiotherapy (RT).
  
  
  METHODS
  We retrospectively reviewed the records of 46 patients who were treated with RT for pathologically confirmed localized stage IE marginal zone B-cell lymphoma of MALT. The radiation dose ranged from 21.6 to 45 Gy (median, 30.6 Gy) at 1.8-2.0 Gy per fraction. Median follow-up duration was 32.3 months (range, 3.1-113.6 months).
  
  
  RESULTS
  Forty-three patients (93%) achieved complete remission (CR), and three patients (7%) achieved partial remission (PR). Five-year relapse-free survival, cause-specific survival, and overall survival were 93%, 100%, and 100%, respectively. Among the patients with CR, two had recurrence at three sites. One patient relapsed locally and was successfully salvaged with reirradiation. The other patient relapsed in a distant site and was successfully treated with six cycles of CHOP chemotherapy. Late complications were noted in four patients. Two patients developed cataracts at 26 and 37 months after completion of RT. The other two patients developed nasolacrimal duct obstructions at 4 and 11 months after completion of RT.
  
  
  CONCLUSIONS
  Our study showed that a modest dose of RT is an excellent treatment modality with low complication and recurrence rates. We suggest that a dose of 30.6 Gy is tolerable and sufficient for treating orbital MALT lymphoma. Even following recurrence, successful salvage is possible with RT or chemotherapy.
authors.affiliation: Department of Radiation Oncology, College of Medicine, The Catholic University of Korea, Seoul, Korea.
authors.forename: Seok Hyun
authors.initials: SH
authors.lastname: Son
authors.forename: Byung Ock
authors.initials: BO
authors.lastname: Choi
authors.forename: Gi Won
authors.initials: GW
authors.lastname: Kim
authors.forename: Suk Woo
authors.initials: SW
authors.lastname: Yang
authors.forename: Young Seon
authors.initials: YS
authors.lastname: Hong
authors.forename: Ihl Bohng
authors.initials: IB
authors.lastname: Choi
authors.forename: Yeon Sil
authors.initials: YS
authors.lastname: Kim
mesh_terms: D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000627:therapeutic use; D002386:Cataract / Q000209:etiology; D003230:Conjunctival Neoplasms / Q000188:drug therapy* / Q000532:radiotherapy; D003520:Cyclophosphamide / Q000008:administration & dosage; D004317:Doxorubicin / Q000008:administration & dosage; D005142:Eyelid Neoplasms / Q000188:drug therapy* / Q000532:radiotherapy; D005260:Female; D006801:Humans; D007767:Lacrimal Duct Obstruction / Q000209:etiology; D018442:Lymphoma, B-Cell, Marginal Zone / Q000188:drug therapy / Q000532:radiotherapy*; D008297:Male; D008875:Middle Aged; D009918:Orbital Neoplasms / Q000532:radiotherapy*; D011241:Prednisone / Q000008:administration & dosage; D011832:Radiation Injuries / Q000150:complications; D011879:Radiotherapy Dosage; D012074:Remission Induction; D019233:Retreatment / Q000379:methods; D012189:Retrospective Studies; D016879:Salvage Therapy / Q000379:methods; D016896:Treatment Outcome; D014750:Vincristine / Q000008:administration & dosage; D055815:Young Adult
chemical_list: D014750:Vincristine; D004317:Doxorubicin; D003520:Cyclophosphamide; D011241:Prednisone